J.B. Chemicals & Pharmaceuticals Ltd.

NSE: JBCHEPHARM · Healthcare

₹2,416.10

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Neutral 58% confidence

Strong technical momentum offset by Q4 profit collapse, modest earnings growth, and unproven merger synergies; Q1 FY27 results are decisive.

Strongest bull point

Stock is 21.45% above 200-day EMA in bullish stack with 26% six-month outperformance, elevated volume, and Q3 showed 11% revenue and 22% profit growth with margin expansion.

Strongest bear point

Q4 FY2026 profit crashed 30.42% YoY despite full-year growth narrative, FY2026 earnings growth of only 5.87% revenue and 7.56% profit is modest, and Torrent merger introduces execution risk with no quantified synergies.

Technical Forecast · next 10 trading days

Expected

₹2,416.10 0.0%

Range

₹2,416.10 – ₹2,416.10

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on JBCHEPHARM, misses included

Neutral 28 Sep 2026 → now Scores 28 Oct 2026

₹2,408.90 → ₹2,416.10 +0.3%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare